Cancer-Breast-Triple Negative Breast Neoplasms
| Title: | Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy |
| Description: | This study investigates the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and gemcitabine (GC therapy) for patients with metastatic triple negative breast cancer. |
| Drug/Procedure: | Trilaciclib; Gemcitabine; Carboplatin |
| NCT Number: | 02978716 |
| Notes: | Phase 2 |
| Start Date: | 3/27/17 |
| Status: | Active, not recruiting |
| Principal Name: | Kerry Pulver, MD |
| Contact Name: | Erin Hawks, CCRC |
| Phone: | (208)367-7165 |